← Back to Search

Ancillary-correlative (renal tumor classification, biology) for Angiolipoma

N/A

Recruiting

Led By Elizabeth A Mullen

Research Sponsored by Children's Oncology Group

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years from study enrollment

Awards & highlights

No Placebo-Only Group

Summary

This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.

Eligible Conditions

Angiolipoma
Wilms Tumor
Infantile renal fibrosarcoma
Kidney Cancer
Renal Tumor of Infancy
Metanephric Stromal Tumor
Kidney Cell Carcinoma
Rhabdoid Tumor
Congenital Mesoblastic Nephroma
Cystic Nephroma
Clear Cell Sarcoma of the Kidney
Nephroblastoma
Diffuse Hyperplastic Perilobar Nephroblastomatosis
Extrarenal Rhabdoid Tumor
Kidney Carcinoma
Kidney Tumors
Kidney Oncocytoma
Metanephric Adenofibroma
Metanephric Adenoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years from study enrollment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years from study enrollment

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years from study enrollment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Event-free survival

Overall survival

Secondary study objectives

Loss of heterozygosity (LOH testing discontinued as of April 2014)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Ancillary-correlative (renal tumor classification, biology)Experimental Treatment2 Interventions

Tumor tissue, blood, and urine samples are collected for research studies, including immunohistochemistry. CT scans and MRIs are also performed. Loss of heterozygosity analyses (chromosome 1p and 16q) are performed by extraction of DNA. DNA polymorphisms are assayed by polymerase chain reaction using standard methodology. Leftover specimens are archived for future studies. (LOH and INI1 testing discontinued as of April 2014)

Do I qualify?Apply below to find out